Celsion Corporation (CLSN) Quote

farrell90, sorry for the delayed response. I was planning to hit you back during Happy Hour last Friday but missed that window of opportunity.

Anyway, since I was not the finder of the link, I don't feel like I should share it directly. However, I recall that you are a good Googler so you should be able to find the info by searching the STP-Press website for recent EEZ (or ZEE in Portuguese) information.

Please let me know that you saw this, and good luck.



.

The typical gap and trap.

lol....


it worked out just great!!!!!


Im a day trader, usually sell all positions intraday unless something is so great I feel I must hold....lol

and thats not too many too often


the markets algo's are set on kill

and offerings are common on stocks like these


sooo, profit takers win!! even if small gains, they add up, and are nuch better than losses of any size

holding and holding hasnt worked well for me or many

like TWTR I SOLD 16k shares @ $53 close to break even now look $47

I would be down around -$100k

NO THANKS elon

How's this working out for you?

https://finviz.com/quote.ashx?t=CLSN

looks like OS traded today

https://twitter.com/READY_2_PROFIT/status/1511399414497218566

https://ih.advfn.com/stock-market/NASDAQ/celsion-CLSN/stock-news/87762622/brookline-capital-markets-remains-a-buy-on-celsion

Their effort was to avoid being delisted JMO

OVER!
Years ago I sold just shy of $10.00
Only thing that will move this stock will be GEN1

it is over for this Trash!,, belongs to the trashcan!.

CLSN voting request1?..
did you receive CLSN shareholder vote notice, please do not vote for R/S?... these criminals continue to exploit shareholders with R/S bullshit, No company that employ R/S ever progressed, very rare, if CLSN goes to R/S, it is over!.

WITHOUT R/S they have to clean up the company, so vote against R/S!.

I agree.

Celsion Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform
8:00 AM ET 9/2/21 | GlobeNewswire

Celsion Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform

Results Indicate Induction of Adaptive Immune Response Against SARS-CoV-2

Company Plans Additional Development Work to Further Optimize its Vaccine Platform Through Vector Compositions, Delivery Route, Dosing and Dosing Frequency, and Use of Molecular Adjuvant

LAWRENCEVILLE, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced results from preclinical in vivo studies showing production of antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2 when immunizing BALB/c mice with the Company's next-generation PLACCINE DNA vaccine platform. Moreover, the antibodies to SARS-CoV-2 spike antigen prevented the infection of cultured cells in a viral neutralization assay. The production of antibodies predicts the ability of PLACCINE to protect against SARS-CoV-2 exposure, and the elicitation of cytotoxic T-cell response shows the vaccine's potential to eradicate cells infected with SARS-CoV-2.

These findings demonstrate the potential immunogenicity of Celsion's PLACCINE DNA vaccine, which is intended to provide broad-spectrum protection and resistance against variants by incorporating multiple viral antigens, to improve vaccine stability at storage temperatures of 4(o) C and above, and to facilitate cheaper and easier manufacturing. Celsion expects to report these data at the International Vaccines Conference to be held on October 19 -- 21, 2021.

"In an effort to establish a suite of platform technologies, we have produced and characterized a family of DNA vaccine vectors expressing one or more SARS-CoV-2 surface antigens or proteins with or without immune modifiers or agents to improve vaccine quality," said Khursheed Anwer, PhD, Celsion's Executive Vice President and Chief Science Officer. "In addition, we are developing an intramuscular vaccine based on a specialized synthetic delivery system that yields high levels of viral proteins to generate the desired immune response. This formulation does not require a separate delivery device, such as electroporation, for administration. We are pleased with the immunogenicity data from our recent preclinical studies and plan to continue to share progress from ongoing in vivo studies intended to further optimize the PLACCINE DNA vaccine activity through vector design, delivery route, dose levels and dosing frequency, as well as adjuvant quality. If successful, our immediate goal is to validate our program with IND-enabling studies."

Michael H. Tardugno, Celsion's Chairman, President and Chief Executive Officer, said, "Our DNA-based vaccine is designed to improve the breadth of immune response by targeting multiple antigens of a pathogen or multiple mutants of the same antigen. The findings we are reporting today are encouraging and demonstrate that the immune response to the PLACCINE DNA vaccine is consistent with our vaccine design goals. We look forward to sharing our progress as we conduct further studies to optimize vector design, dosing and delivery with the goal of filing an Investigational New Drug application with the U.S. Food and Drug Administration early next year.

"Importantly, based on our experience with GEN-1, our DNA plasmid immunotherapy, we fully expect that our platform will be both cost-effective and scalable, allowing for stability across a reasonable and readily achievable temperature range that addresses global vaccine storage and distribution needs. A successful proof of concept using mRNA vaccines as a standard will provide Celsion with the scientific basis to launch a vaccine program to address a range of unaddressed serious infectious diseases," Mr. Tardugno added.

About the PLACCINE platform

PLACCINE is Celsion's proprietary plasmid and DNA delivery technology and the subject of a provisional patent application that covers a broad range of next-generation DNA vaccines. An adaptation of the Company's TheraPlas technology, PLACCINE is a DNA vaccine technology platform characterized by a single plasmid DNA with multiple coding regions. The plasmid vector is designed to express multiple pathogen antigens along with a potent immune modifier. It is delivered via a synthetic delivery system and has the potential to be easily modified to create vaccines against a multitude of infectious diseases, addressing:
-- Viral Mutations: PLACCINE may offer broad-spectrum and mutational
resistance (variants) by targeting multiple antigens on a single plasmid
vector.

-- Enhanced Efficacy: The potent immune modifiers such as cytokines and
chemokines may improve humoral and cellular responses to viral antigens
and can be incorporated in the plasmid.

-- Durable Efficacy: PLACCINE delivers a DNA plasmid-based antigen that can
result in durable antigen exposure and a robust vaccine response to viral
antigens.

-- Storage & Distribution: PLACCINE allows for stability that is compatible
with manageable vaccine storage and distribution.

-- Dosing & Administration: PLACCINE is a synthetic delivery system that
should require a simple injection that does not require viruses or
special equipment to deliver its payload.

About Celsion Corporation

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox(R) , a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit www.celsion.com.

Forward-Looking Statements

Forward-looking statements in this news release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, statements relating to the offering and the use of proceeds therefrom, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in the Celsion's periodic filings with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

CONTACTS:

Celsion Corporation

Jeffrey W. Church

Executive Vice President and CFO

609-482-2455

jchurch@celsion.com

LHA Investor Relations

Kim Sutton Golodetz

212-838-3777

kgolodetz@lhai.com

> Dow Jones Newswires

September 02, 2021 08:00 ET (12:00 GMT)

Strong buy low $3. soon.....

CLSN buy 1.0900

nice buy off of the double bottom support level on the daily chart...
such a textbook chart right now in many ways...


https://finance.yahoo.com/quote/CLSN/profile?p=CLSN

https://www.barchart.com/stocks/quotes/CLSN

https://finviz.com/quote.ashx?t=CLSN

https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=CLSN

https://stockcharts.com/c-sc/sc?chart=CLSN,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b

https://www.barchart.com/etfs-funds/quotes/CLSN/technical-chart?plot=CANDLE&volume=toCLSN&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=TREND&sym=CLSN&grid=1&height=500&studyheight=100&timeframe=2%20Months




normal chart









log chart









normal chart








log chart

CLSN...$1.54...in the P/M..Been adding the $1 range dip off the $2.22 alert...looking for the rebound here...imo...we shall see...:party:
[6:28 AM]
georgie18 — 03/15/2021
CLSN...$2.22...Taking a starter here...Looking for a Double Top Breakout and the Psar to flip Bullish...imo...we shall see... :party:

I believe it to be a negotiated price. It least we know the entry price is 1.30 at it's low. CLSN going much higher. And news will skyrocket this pps.

how did they figure $1.30 per share, why not more?/

CLSN...$1.39...added here...:party:

Is it standard-operating-procedure of this company to proclaim in a cc:

Subsequent to year end, we raised over $43 million in gross proceeds from the sale of common stock and when factoring in an estimate of first quarter spending, we currently have approximately $56 million in cash on our balance sheet. This provides an operating runway through 2023 at our current cash usage of $4.5 million per quarter.

https://seekingalpha.com/article/4415104-celsion-corporation-clsn-ceo-michael-tardugno-on-q4-2020-results-earnings-call-transcript?amp=&utm_medium=referral&utm_source=dowjonesnewswire.com

And then dump a $100M ATM on we plebians immediately afterward??

https://www.otcmarkets.com/filing/html?id=14814603&guid=BMpaUnLBMuT6M3h

Well, Isn't that special...

I like the entry. Big prospects here. Huge potential of a medical break through. If that is the case...

CLSN...$2.22...Taking a starter here...Looking for a Double Top Breakout and the Psar to flip Bullish...imo...we shall see...

Chart...https://schrts.co/KtbZxpTe ...

Look @ the options. Big bet this is going much higher.

I made a quick flip this AM pre... will buy a TON now ... after market looks ripe...

not today
cant break 2.50s in pre
shortie in control

$10.00 on the way...

The new GEN-1 technology is groundbreaking.

Video:

Celsion Corporation ($CLSN) has received Fast Track designation from the U.S. FDA for "GEN-1" its DNA-mediated treatment of advanced ovarian cancer. The fundamental science is GROUNDBREAKING! They design a specific DNA-based immunotherapy to specifically target the DNA of each individual patient's cancer, which spares the surrounding healthy tissue. The humanitarian value is priceless and the business value has potentially unlimited upside, as this approach gets extended to cancers other than ovarian cancer, over time. As a scientist, I foresee many licenses for this technology to be used by other companies curing other cancers in the future.

* * $CLSN Video Chart 02-22-2021 * *

Link to Video - click here to watch the technical chart video

Let’s hope you are right

$5 PLUS ON ITS WAY

February 22, 2021 08:57 AM ET

The FDA has designated Fast Track status to Celsion Corporation's (NASDAQ: CLSN) GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer.

Fast Track status provides more frequent interaction with the FDA review team and a rolling review of the marketing application.

GEN-1 is currently in Phase 2 OVATION study, which combines GEN-1 with standard-of-care neoadjuvant chemotherapy in patients newly diagnosed with Stage 3/4 ovarian cancer.

The study's primary endpoint is two show the equivalent of a 33% improvement in progression-free survival compared with the control arm (standard of care alone).

Price Action: CLSN shares rally 74.7% at $3.32 in premarket trading on the last check Monday.

$CLSN is screaming for the top after the company announced that it has received Fast Track Designation for GEN-1. https://cnafinance.com/clsn-stock-rocketing-on-fast-track-designation/

* * $CLSN Video Chart 02-11-2021 * *

Link to Video - click here to watch the technical chart video

look out. big shorts here too. Oh BOY

I just took a hard look at the option chains...They look great. Call side action.

Just profit takers from Monday's .50 up day ,

Correction?

Risk/Reward play here.

CLSN LONG

could be a squeeze from the shorts that entered on the high vol day at the end of January. That was some amazing vol. I was surprised it only went to 2.80 on that run. I've seen this run up to $6 and $7 before.

I think a slow but steady climb is coming , I seen some on ST are talking about a possible short squeeze happening

waiting on this one to go. Seems like its about ready but who knows? lol

wait till Monday big news coming, buy now before too late.

* * $CLSN Video Chart 01-26-2021 * *

Link to Video - click here to watch the technical chart video

im better than you bought at 0.85 sold at $4.89 3 mil ..do you believe me ???

bought at .88 Sold at 2.75 1.6 mil on one day of trade

Really? This stock was once 500$ a share? This seeking alpha article says so...Explains how Thermodox came into being and failed the first phase III but was adjusted and found success with a new approach.

Best

insert-text-here.

Tutes are planning to make money so relax!

I was disappointed to see this offering of 25.9m shares at $1.35 but I see around 30m shares traded today and it's still above the offering price so that suggests a strong floor at this price.

https://ih.advfn.com/stock-market/NASDAQ/celsion-CLSN/stock-news/84150415/celsion-corporation-announces-35-million-register

time to push this stock higher

A good buying day. Big news on a buyout coming

* * $CLSN Video Chart 01-21-2021 * *

Link to Video - click here to watch the technical chart video